Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.6% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 3.6% during trading on Tuesday . The company traded as low as $6.45 and last traded at $6.50. 5,126,260 shares were traded during trading, a decline of 65% from the average session volume of 14,725,752 shares. The stock had previously closed at $6.74.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RXRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Price Performance

The stock’s 50-day simple moving average is $6.92 and its two-hundred day simple moving average is $6.96. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of -4.18 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,288,380.78. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,894 shares of company stock valued at $317,139. Corporate insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RXRX. ARK Investment Management LLC lifted its holdings in Recursion Pharmaceuticals by 16.4% in the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after acquiring an additional 4,626,268 shares during the last quarter. State Street Corp lifted its stake in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Lingotto Investment Management LLP lifted its stake in shares of Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the 2nd quarter worth $8,250,000. Finally, Perceptive Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at about $5,769,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.